PE20151284A1 - Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco - Google Patents

Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Info

Publication number
PE20151284A1
PE20151284A1 PE2015001729A PE2015001729A PE20151284A1 PE 20151284 A1 PE20151284 A1 PE 20151284A1 PE 2015001729 A PE2015001729 A PE 2015001729A PE 2015001729 A PE2015001729 A PE 2015001729A PE 20151284 A1 PE20151284 A1 PE 20151284A1
Authority
PE
Peru
Prior art keywords
injection
prevent
dilution
sodium chloride
contraction
Prior art date
Application number
PE2015001729A
Other languages
English (en)
Inventor
Chandra A Webb
Julie Zerfas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20151284A1 publication Critical patent/PE20151284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion proporciona metodos para la preparacion de formulaciones farmaceuticas para inyeccion tal que en la inyeccion la formulacion no provoque la aglutinacion de eritrocitos, hemolisis, y/o contraccion de celulas. Para prevenir [a aglutinacion, una formulacion farmaceutica preparada para inyeccion necesita tener una fuerza ionica suficiente. Para prevenir la hemolisis o la contraccion de celulas, una formulacion farmaceutica preparada para inyeccion necesita ser casi isotonica con respecto al plasma. La invencion proporciona metodos que preparan formulaciones farmaceuticas para inyeccion que tienen tanto la fuerza ionica suficiente para prevenir la aglutinacion y la tonicidad requerida para prevenir hemolisis o deshidratacion o contraccion de celulas significativas. Los metodos presentes involucran el uso de soluciones de cloruro de sodio que son alrededor de 25 MM hasta alrededor de 150 mM para reconstitucion de tortas liofilizadas (u otras formulaciones farmaceuticas no liquidas) en solucion o para dilucion de soluciones de formulacion farmaceutica
PE2015001729A 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco PE20151284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73222105P 2005-11-01 2005-11-01

Publications (1)

Publication Number Publication Date
PE20151284A1 true PE20151284A1 (es) 2015-10-05

Family

ID=37801586

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2011000653A PE20110803A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
PE2015001729A PE20151284A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
PE2006001318A PE20070714A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011000653A PE20110803A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2006001318A PE20070714A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Country Status (31)

Country Link
US (4) US20070135343A1 (es)
EP (3) EP3593790A1 (es)
JP (1) JP5555425B2 (es)
KR (2) KR20110128957A (es)
CN (1) CN101351190B (es)
AR (2) AR056748A1 (es)
AU (1) AU2006308921C1 (es)
BR (1) BRPI0618133A2 (es)
CA (1) CA2626531C (es)
CR (1) CR9958A (es)
DK (2) DK3225233T3 (es)
EC (1) ECSP088485A (es)
ES (2) ES2627684T5 (es)
FI (1) FI1942868T4 (es)
FR (1) FR20C1005I1 (es)
GT (1) GT200800037A (es)
HK (1) HK1245090B (es)
HU (4) HUE033949T2 (es)
IL (1) IL190843A (es)
LU (1) LUC00035I2 (es)
MY (1) MY184364A (es)
NO (1) NO347263B1 (es)
NZ (1) NZ567685A (es)
PE (3) PE20110803A1 (es)
PL (2) PL3225233T3 (es)
PT (2) PT1942868T (es)
RU (1) RU2432157C2 (es)
SI (2) SI1942868T2 (es)
TW (1) TWI480063B (es)
UA (1) UA97234C2 (es)
WO (1) WO2007053533A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110128957A (ko) 2005-11-01 2011-11-30 와이어쓰 엘엘씨 약물 재구성 또는 희석을 위한 염화나트륨 용액
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8431011B2 (en) * 2008-01-31 2013-04-30 Abbott Diabetes Care Inc. Method for automatically and rapidly distinguishing between control and sample solutions in a biosensor strip
CA2780554C (en) * 2009-11-17 2017-08-15 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination
US9427186B2 (en) 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
SG182468A1 (en) 2010-01-15 2012-08-30 Kirin Amgen Inc Antibody formulation and therapeutic regimens
JP5937523B2 (ja) 2010-03-01 2016-06-22 サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． 濃縮されたタンパク質製剤およびその使用
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
WO2014052490A1 (en) * 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
CN105283202B (zh) 2013-03-11 2019-04-23 安都磁学有限公司 用于淋巴结检测的低渗溶液
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
EP2968498A4 (en) * 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
KR102385372B1 (ko) * 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
US9351945B1 (en) * 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
GB2536703B (en) * 2015-03-27 2020-12-02 Ge Healthcare Bio Sciences Ab Method for baseline correction in a chromatogram
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
EP4085866A3 (en) 2015-06-04 2023-01-18 Endomagnetics Ltd. Marker materials and forms for magnetic marker localization
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
CA3130700A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US20200345658A1 (en) * 2019-05-01 2020-11-05 Southwest Research Institute Compositions Of Dimethyl Trisulfide (DMTS) As A Cyanide Antidote
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
US4364861A (en) 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
AU2005225000A1 (en) * 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
KR20110128957A (ko) 2005-11-01 2011-11-30 와이어쓰 엘엘씨 약물 재구성 또는 희석을 위한 염화나트륨 용액

Also Published As

Publication number Publication date
UA97234C2 (ru) 2012-01-25
ES2627684T3 (es) 2017-07-31
LUC00035I2 (es) 2017-12-01
AU2006308921B2 (en) 2012-07-19
DK1942868T3 (en) 2017-06-26
EP3225233A1 (en) 2017-10-04
NZ567685A (en) 2011-07-29
US20200138952A1 (en) 2020-05-07
RU2432157C2 (ru) 2011-10-27
NO20082180A (no) 2008-07-04
CN101351190A (zh) 2009-01-21
US20070135343A1 (en) 2007-06-14
FR20C1005I1 (fr) 2020-03-20
CR9958A (es) 2008-07-29
IL190843A0 (en) 2008-11-03
HK1245090B (zh) 2020-04-09
LUC00035I1 (es) 2017-09-28
MY184364A (en) 2021-04-01
DK1942868T5 (da) 2024-01-08
DK1942868T4 (da) 2023-11-06
CA2626531A1 (en) 2007-05-10
GT200800037A (es) 2008-10-01
KR101126670B1 (ko) 2012-04-23
PL1942868T3 (pl) 2017-09-29
FI1942868T4 (fi) 2023-10-12
EP1942868B2 (en) 2023-10-04
PT3225233T (pt) 2019-10-24
IL190843A (en) 2013-08-29
WO2007053533A3 (en) 2007-12-06
EP3593790A1 (en) 2020-01-15
SI3225233T1 (sl) 2019-10-30
HUE033949T2 (hu) 2018-01-29
EP1942868A2 (en) 2008-07-16
WO2007053533A8 (en) 2008-07-24
AR056748A1 (es) 2007-10-24
CA2626531C (en) 2011-11-29
WO2007053533A2 (en) 2007-05-10
PE20070714A1 (es) 2007-07-20
NO347263B1 (no) 2023-08-14
TWI480063B (zh) 2015-04-11
HUS2000003I1 (hu) 2020-02-28
JP5555425B2 (ja) 2014-07-23
SI1942868T2 (sl) 2023-12-29
PE20110803A1 (es) 2011-11-07
AR112443A2 (es) 2019-10-30
PL1942868T5 (pl) 2023-12-27
EP1942868B1 (en) 2017-04-19
PL3225233T3 (pl) 2019-12-31
ES2627684T5 (es) 2024-04-29
PT1942868T (pt) 2017-06-16
DK3225233T3 (da) 2019-10-14
HUS1700035I1 (hu) 2017-11-28
EP3225233B1 (en) 2019-08-14
BRPI0618133A2 (pt) 2011-08-16
ECSP088485A (es) 2008-06-30
CN101351190B (zh) 2013-01-02
JP2009513705A (ja) 2009-04-02
SI1942868T1 (sl) 2017-07-31
TW200803915A (en) 2008-01-16
US20200338199A1 (en) 2020-10-29
RU2008119514A (ru) 2009-12-10
ES2749574T3 (es) 2020-03-23
HUE045421T2 (hu) 2019-12-30
AU2006308921A1 (en) 2007-05-10
NO20082180L (no) 2008-07-04
KR20110128957A (ko) 2011-11-30
AU2006308921C1 (en) 2013-01-24
KR20080065689A (ko) 2008-07-14
US20170021022A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
PE20151284A1 (es) Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
HUP9902952A1 (hu) Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása
DE69906084D1 (de) Ibuprofen enthaltende schnelllösliche zusammensetzungen mit analgetischer wirkung
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
EA200970274A1 (ru) Способы введения гипогликемических средств с длительным действием
EA200301004A1 (ru) Восстанавливаемая композиция для парентерального введения, содержащая ингибитор cox-2 (циклооксигеназа-2)
EA200400819A1 (ru) Парентеральная композиция парацетамола
RS50241B (sr) Mikrogranule nerastvorljive u želudačnim sokovima, postupak za njihovo dobijanje i farmaceutski preparati
Liu et al. Cytoprotective properties of novel nonpeptide calpain inhibitors in renal cells
ES2418459R1 (es) Relacionando agregacion proteica con supervivencia de levadura
AR031010A1 (es) Una composicion farmaceutica, util para inhibir el dano celular
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
EE200200042A (et) Ravimkoostis ja meetod selle valmistamiseks
WO2004014318A3 (en) Levothyroxine compositions and methods
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту
BR112022025192A8 (pt) Derivado de insulina asparte, e método de preparação para o mesmo e uso do mesmo
ECSP982720A (es) Formulacion que contiene un opioide en combinacion con un agonista adrenergico y su utilizacion como analgesico
EA200500608A1 (ru) Новая ассоциация гетероциклического соединения и антиоксидантного агента и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
FC Refusal